华泰联合证券有限责任公司 关于奥精医疗科技股份有限公司 使用部分闲置募集资金暂时补充流动资金的 核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为 奥精医疗科技股份有限公司（以下简称"奥精医疗"或"公司"）首次公开发行 股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科 创板股票上市规则》及《上海证券交易所科创板上市公司自律监管指引第 1 号— —规范运作》等有关规定，对公司本次拟使用部分闲置募集资金暂时补充流动资 金事项进行了审慎核查，核查情况如下： 一、募集资金的基本情况 经中国证券监督管理委员会证监许可[2021]1219 号《关于同意奥精医疗科技 股份有限公司首次公开发行股票注册的批复》批准，公司向社会公开发行人民币 普通股（A 股）股票 3,333.3334 万股。截至 2021 年 5 月 17 日止，公司已向社会 公开发行人民币普通股（A 股）股票 3,333.3334 万股，每股发行价格 16.43 元， 募集资金总额为人民币 547,666,677.62 元。公司为本次股票发行累计发生发行费 用 49,653,236.30 元（此处为含税金额，包 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥100,240,888.10, a decrease of 15.05% compared to ¥118,005,140.62 in the same period last year[15]. - The net profit attributable to shareholders of the listed company was ¥9,222,057.43, down 73.96% from ¥35,415,096.37 year-on-year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,233,188.38, a decline of 95.51% compared to ¥27,465,757.13 in the previous year[15]. - The net cash flow from operating activities was -¥9,417,807.16, a significant decrease of 130.48% from ¥30,901,100.80 in the same period last year[15]. - The basic earnings per share for the first half of 2024 decreased by 74.07% to CNY 0.07 compared to CNY 0.27 in the same period last year[16]. - The net profit attributable to shareholders for the first half of 2024 was CNY 9.22 million, a decrease of 73.96% year-on-year, primarily due to a decline in operating income and increased management expenses[16]. - Operating revenue for the first half of 2024 decreased by 15.05% year-on-year, attributed to adverse market conditions[16]. - The net cash flow from operating activities for the first half of 2024 was -CNY 9.42 million, a decline of 130.48% compared to the same period last year, mainly due to reduced sales collections[16]. - The company's total comprehensive income for the first half of 2024 was ¥4,939,194.34, down from ¥33,743,839.37 in the same period of 2023, indicating a decline of approximately 85%[105]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,562,494,453.91, reflecting a growth of 2.37% compared to ¥1,526,256,853.43 at the end of the previous year[15]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,427,383,312.73, an increase of 3.28% from ¥1,382,079,651.19 at the end of the previous year[15]. - Cash and cash equivalents increased to ¥181,241,583.48, representing 11.60% of total assets, up 12.40% year-on-year[44]. - Accounts receivable rose to ¥86,462,994.42, accounting for 5.53% of total assets, with a significant increase of 45.88% compared to the previous year[44]. - The company's total liabilities decreased to ¥48.04 million from ¥50.79 million, indicating a reduction of approximately 5.4%[98]. Research and Development - Research and development expenditure accounted for 16.69% of operating revenue, an increase of 1.7 percentage points compared to the previous year[16]. - The company achieved a total R&D investment of ¥16,732,657.88, a decrease of 5.42% compared to the previous year, primarily due to reduced testing and inspection costs[25]. - The R&D team has expanded to 23 members, with R&D personnel accounting for 10.55% of the total workforce, compared to 12.58% in the previous year[32]. - The company has received 5 invention patents and 1 utility model patent during the reporting period, bringing the total to 75 invention patents and 47 utility model patents[24]. - The company is progressing with several R&D projects, including the collagen sponge project, which is currently in the review stage with the National Medical Products Administration[24]. Market and Competitive Position - The company is actively expanding its market presence in high-value medical consumables and is involved in centralized procurement initiatives[20]. - The market size of China's medical device industry reached 1.18 trillion yuan in 2023, with a year-on-year growth of 10.28%[22]. - The company has established a leading position in the domestic market for artificial bone repair materials, with three Class III medical device registrations in China and one FDA 510(k) market approval in the U.S.[34]. - The company has expanded its sales network to nearly 1,800 terminal hospitals and established stable partnerships with over 800 quality distributors[34]. - The company is actively engaging with high-growth international markets, including North America, Latin America, Southeast Asia, the Middle East, and Africa[36]. Corporate Governance and Compliance - There were no significant adverse risk factors impacting the company during the reporting period[3]. - The report did not include any plans for profit distribution or capital increase from reserves[4]. - The company has not disclosed any special arrangements for corporate governance or non-operating fund occupation by controlling shareholders[4]. - The company has established a comprehensive internal control system and strengthened management to improve operational efficiency and decision-making accuracy[37]. - The company has implemented a high-standard quality management system and has obtained ISO 13485:2016 certification for its medical devices[34]. Shareholder Commitments and Stock Management - The actual controllers and shareholders have committed to a 36-month lock-up period for their shares following the company's IPO[55]. - The company commits to not transferring or managing shares for 36 months post-IPO, with potential extensions based on stock performance[57]. - The company will retain any profits from share sales if commitments are violated, and may withhold payments to the violator until obligations are met[59]. - The company will ensure that any share reduction plans are disclosed in advance, maintaining transparency with regulatory bodies[59]. - The actual controller's single investment in shares must not be less than 20% of the total cash dividends received since the company's listing[63]. Environmental and Social Responsibility - The company has invested ¥3,000,000 in environmental protection during the reporting period[52]. - The company has implemented measures to reduce carbon emissions by optimizing production processes and utilizing energy-efficient equipment[54]. - The company has not reported any specific carbon dioxide equivalent emissions reductions during the reporting period[54]. - The company is focused on optimizing raw material and equipment utilization to lower resource consumption[54]. Financial Reporting and Accounting Policies - The financial statements are prepared in accordance with the relevant accounting standards and regulations set by the Ministry of Finance and the China Securities Regulatory Commission[128]. - The company recognizes revenue when control of goods or services is transferred to customers, indicating fulfillment of performance obligations[191]. - The company assesses impairment of contract-related assets when their carrying value exceeds the expected remaining consideration[196]. - The company uses observable inputs for fair value measurement of financial instruments, prioritizing relevant observable inputs unless they are not available[151]. - The company applies a perpetual inventory system for inventory management, using the weighted average method for inventory cost calculation[157].

奥精医疗科技股份有限公司 章 程 二〇二四年八月 | | | | 目 | | 录 1 | | --- | --- | --- | | 第一章 | 总 | 则 3 | | 第二章 | | 经营宗旨和范围 4 | | 第三章 | 股 | 份 4 | | 第一节 | | 股份发行 4 | | 第二节 | | 股份增减和回购 6 | | 第三节 | | 股份转让 7 | | 第四章 | | 股东和股东大会 9 | | 第一节 | | 股东 9 | | 第二节 | | 股东大会的一般规定 11 | | 第三节 | | 股东大会的召集 15 | | 第四节 | | 股东大会的提案与通知 16 | | 第五节 | | 股东大会的召开 18 | | 第六节 | | 股东大会的表决和决议 21 | | 第五章 | | 董事会 25 | | 第一节 | 董 | 事 25 | | 第二节 | | 董事会 28 | | 第六章 | | 公司高级管理人员 34 | | 第一节 | | 一般规定 34 | | 第二节 | | 总经理、副总经理 34 | | 第三节 | | 董事会秘书 36 | | 第七章 | | 监事会 37 | | ...

证券代码：688613 证券简称：奥精医疗 公告编号：2024-036 奥精医疗科技股份有限公司 关于召开 2024 年第三次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一） 股东大会类型和届次 2024 年第三次临时股东大会 召开日期时间：2024 年 9 月 12 日 14 点 30 分 召开地点：北京市大兴区永旺西路 26 号院 2 号楼 4 层会议室 （五） 网络投票的系统、起止日期和投票时间。 重要内容提示： 一、 召开会议的基本情况 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2024年9月12日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为 ...

证券代码：688613 证券简称：奥精医疗 公告编号：2024-032 奥精医疗科技股份有限公司 自愿披露关于公司产品在马来西亚获得注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于2024年5月向马来西亚药品 监督管理局(以下简称"MDA")递交了公司BonGold™人工骨修复材料的注册申报资 料。公司于近日收到MDA通知，公司BonGold™人工骨修复材料获得MDA的批准。现将 相关情况公告如下： 一、注册证内容 1、BonGold™人工骨修复材料 注册证编号：GD4650624-178347 产品名称：人工骨修复材料 证件有效期：2024.08.08-2029.08.07 产品分类：Class D 二、 医疗器械基本情况 1、BonGold™人工骨修复材料 本次获得马来西亚注册证的BonGold™人工骨修复材料是基于奥精医疗具有完全 自主知识产权的体外仿生矿化技术研发和生产的一种仿生矿化胶原人工骨修复材 料，在组成成分和微观结构上均对人体天然骨组织高度仿生。产 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司董事会 2024 年 8 月17日 奥精医疗科技股份有限公司（以下简称"公司"）于2023年8月22日分别 召开了第二届董事会第五次会议、第二届监事会第五次会议，会议审议通过了 《关于公司使用部分闲置募集资金暂时补充流动资金的议案》，同意公司在确 保不影响募集资金投资项目建设进度的前提下，使用闲置募集资金不超过人民 币3,000.00万元暂时用于补充公司流动资金，使用期限为自公司董事会审议通 过之日起12个月内。独立董事对上述议案发表了明确的同意意见，保荐机构对 上述事项发表了核查意见。具体内容详见公司于2023年8月23日在上海证券交易 所官网（www.sse.com.cn）披露的《奥精医疗科技股份有限公司关于公司使用 部分闲置募集资金暂时补充流动资金的公告》（公告编号：2023-047）。 根据董事会决议，公司在规定期限内使用24,184,131.57元闲置募集资金临 时补充流动资金，并对资金进行了合理的安排与使用，资金运用情况良好，未 影响募集资 ...

Financial Data and Key Metrics - Revenue in 2023 decreased compared to 2022 due to market conditions and industry governance, with a notable decline in net profit primarily due to equity incentive share-based payments [9] - The company expects the impact on net profit to continue into this year, with related expenses dropping significantly next year, estimated to be around 8 million RMB this year and 3-4 million RMB next year [9] Business Line Data and Key Metrics - Orthopedic products account for nearly 70% of revenue, neurosurgery around 20%, and dental products about 10% [11] - The company's dental materials business is expected to double in revenue this year due to synergies from the acquisition of a German implant company [32][35] Market Data and Key Metrics - The company's products are distributed through 750+ dealers, covering over 900 hospitals nationwide, excluding Hong Kong, Macau, and Taiwan [10] - The national centralized procurement (集采) for orthopedic products has doubled the number of hospitals using the company's products, from less than 700 to nearly 1,500 [10] Company Strategy and Industry Competition - The company is focusing on cost reduction and efficiency improvement, including building new production lines in Shandong to lower costs [20] - The company is leveraging the national centralized procurement to increase market penetration and expects significant growth in product usage [12][15] - The company is also expanding internationally, with plans to obtain market access in 3-5 countries this year [37] Management Commentary on Operating Environment and Future Outlook - Management believes that the centralized procurement will lead to increased clinical usage of their products, replacing autologous bone and allograft materials [15][17] - The company is optimistic about the long-term growth of the dental implant market, expecting high-speed growth over the next 5-10 years [26] Other Important Information - The company is developing new products, including collagen sponge and animal-derived bone materials, with expected approvals in Q3 2024 [23] - The company has acquired a German implant company, which is expected to enhance its product portfolio and market position [24][26] Q&A Session Question: Synergies from the acquisition of the German implant company - The acquisition is expected to significantly boost the dental materials business, with revenue potentially doubling this year [32][35] - The company plans to integrate the German implant products with its existing dental materials to provide a comprehensive solution to the market [34][35] Question: International expansion plans - The company is working on obtaining market access in 3-5 countries this year and expects to generate some revenue from international markets next year [37][43] - The German implant company's existing certifications and market access in various countries will facilitate the company's international expansion [38][39] Question: Impact of centralized procurement on orthopedic business - The company expects a 15-20% decline in orthopedic revenue this year due to price reductions from centralized procurement, but the impact will be less severe compared to other companies in the industry [49] Question: Future of collagen sponge product - The collagen sponge product is expected to have a wide range of clinical applications and will significantly reduce production costs for the company's core materials [52][55] - The product is also seen as a strategic platform for future developments in regenerative medicine [58]

华泰联合证券有限责任公司 关于奥精医疗科技股份有限公司 使用部分募集资金对全资子公司增资 以实施募投项目的核查意见 为保障募投项目的顺利实施，公司拟以募集资金人民币 3,880.00 万元对潍坊 奥精健康科技有限公司（以下简称"潍坊奥精健康"）进行增资，用于募投项目 "引导骨再生骨修复膜/面团状仿生骨修复材料/骨水泥改性用人工骨粉"和募投 项目"奥精健康科技产业园建设项目"子项目"引导组织再生（GTR）胶原膜"、 "皮肤修护用胶原蛋白敷料"的实施，金额分别为 3,300.00 万元和 580.00 万元； 拟以募集资金人民币 977.00 万元对全资子公司嘉兴奥精生物科技有限公司（以 下简称"嘉兴奥精"）进行增资，用于募投项目"奥精健康科技产业园建设项目" 子项目"引导组织再生（GTR）胶原膜"、"皮肤修护用胶原蛋白敷料"的实施。 本次增资完成后，潍坊奥精健康注册资本将由 500 万元增加至 4,380 万元，公司 仍持有其 100%股权；嘉兴奥精注册资本将由 500 万元增加至 1,477 万元，公司 仍持有其 100%股权。 本次交易系公司对全资子公司增资，不构成关联交易和《上市公司重大资产 重组管理办法 ...

证券代码：688613 证券简称：奥精医疗 公告编号：2024-029 增资标的名称：潍坊奥精健康科技有限公司（以下简称"潍坊奥精健康"）、 嘉兴奥精生物科技有限公司（以下简称"嘉兴奥精"） 资金来源及增资金额：奥精医疗科技股份有限公司（以下简称"公司"、"奥 精医疗"）拟以募集资金人民币 3,880.00 万元对全资子公司潍坊奥精健康进行增 资，用于募投项目"引导骨再生骨修复膜/面团状仿生骨修复材料/骨水泥改性用人 工骨粉"和募投项目"奥精健康科技产业园建设项目"子项目"引导组织再生 （GTR）胶原膜"、"皮肤修护用胶原蛋白敷料"的实施，金额分别为 3,300.00 万 元和 580.00 万元；拟以募集资金人民币 977.00 万元对全资子公司嘉兴奥精进行 增资，用于募投项目"奥精健康科技产业园建设项目"子项目"引导组织再生 （GTR）胶原膜"、"皮肤修护用胶原蛋白敷料"的实施。本次增资完成后，潍坊 奥精健康注册资本将由 500 万元增加至 4,380 万元，公司仍持有其 100%股权； 嘉兴奥精注册资本将由 500 万元增加至 1,477 万元，公司仍持有其 100%股权。 本次增资事项已经公司第二届董 ...

证券代码： 688613 证券简称：奥精医疗 公告编号： 2024-030 二、本次拟新增募集资金专用账户的情况 为满足募投项目的实际开展需要，公司拟在招商银行股份有限公司北京大 兴支行、兴业银行股份有限公司北京中关村支行增设募集资金专项账户，用于 公司募集资金的存储和使用。 董事会授权管理层办理公司与保荐机构、开户银行签订募集资金专项账户 存储监管协议等具体事宜。 三、对公司的影响 本次新增募集资金专用账户的事项，符合中国证券监督管理委员会《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海 证券交易所科创板股票上市规则》、《上海证券交易所科创板上市公司自律监 管规则适用指引第 1 号——规范运作》等法律、法规及规范性文件的要求以及 《奥精医疗科技股份有限公司募集资金管理制度》等相关规定，有利于公司进 一步规范募集资金的管理。专项账户资金的存放与使用将严格遵照中国证券监 督管理委员会、上海证券交易所的相关规定，符合公司长远发展需求和股东利 益。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担 ...